These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 7630182)

  • 21. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia.
    Leone G; Pagano L; Marra R; Di Pietro N; Storti S; Sica S; D'Onofrio G; Ganzina F
    Haematologica; 1989; 74(1):57-61. PubMed ID: 2498185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U; Göldel N; Vehling-Kaiser U
    Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Complete remission in acute promyelocytic leukemia. The advantages of all-trans-retinoic acid compared to conventional chemotherapy].
    Lengfelder E; Simon M; Haase D; Hild F; Hehlmann R
    Dtsch Med Wochenschr; 1994 Aug; 119(34-35):1143-50. PubMed ID: 8076501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.
    MacCallum PK; Davis CL; Rohatiner AZ; Lim J; Gupta RK; Whelan JS; Price CG; Evans ML; Amess JA; Leahy M
    Leukemia; 1993 Oct; 7(10):1496-9. PubMed ID: 8412309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
    Harousseau JL; Milpied N; Brière J; Desablens B; Ghandour C
    Nouv Rev Fr Hematol (1978); 1990; 32(4):227-30. PubMed ID: 2290708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
    Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho AD; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
    Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Wells RJ; Gold SH; Krill CE; Cornelius AS; Byrd RL; Ruymann FB; Feusner J; White ML; Cairo MS
    Leukemia; 1994 Oct; 8(10):1626-30. PubMed ID: 7934157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
    Lemez P; Gáliková J; Haas T
    Neoplasma; 2000; 47(1):41-7. PubMed ID: 10870686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Kreze O
    Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All-trans retinoic acid plus low doses of cytarabine for the treatment of "poor-risk" acute myeloid leukemias.
    Venditti A; Stasi R; Masi M; Del Poeta G; Cox C; Franchi A; Piccioni D; Bruno A; Coppetelli U; Tribalto M
    Ann Hematol; 1993 Feb; 66(2):59-60. PubMed ID: 8448241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
    Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
    Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
    Dekker AW; Nieuwenhuis HK; Verdonck LF
    Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.